Trastuzumab emtansine and stereotactic radiosurgery: An unexpected increase in clinically significant brain edema

Neuro-Oncology

Volumn 16, Issue 7, 2014, Pages 1006-1009

  Carlson, Julie A ^a   Nooruddin, Zohra ^a   Rusthoven, Chad ^a   Elias, Anthony ^a   Borges, Virginia F ^a   Diamond, Jennifer R ^a   Kavanagh, Brian ^a   Kabos, Peter ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

brain metastases; HER2 positive breast cancer; stereotactic radiosurgery; targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BRAIN EDEMA; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; NAUSEA; NEUROLOGIC DISEASE; RADIATION NECROSIS; SHORT TERM MEMORY; SPEECH DISORDER; STEREOTACTIC RADIOSURGERY; TUMOR GROWTH; VOMITING; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BRAIN; BRAIN NEOPLASMS; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NECROSIS; PATHOLOGY; RADIATION RESPONSE; RADIOSURGERY; SECONDARY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN EDEMA; BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MAYTANSINE; MIDDLE AGED; NECROSIS; RADIOSURGERY; RECEPTOR, ERBB-2;

EID: 84902477569     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not329     Document Type: Article

References (27)

1. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immuno-histochemistry in a cohort of 6556 breast cancer tissues. Clinical Breast Cancer. 2004;5(1):63-69.
2. Slamon DJ, Godophin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707- 712.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
4. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26): 2733-2743.
5. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-1791.
6. Olson EM, Najita JS, Sohl J, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013;22(4):525-531.
7. Musolino A, Ciccolallo L, Panebianco M, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117(9): 1837-1846.
8. Duchnowska R, Biernat W, Szostakiewicz B, et al. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist. 2012;17(1):26-35.
9. Muacevic A, Kreth FW, Tonn JC, et al. Stereotactic radiosurgery for multiple brain metastases from breast carcinoma. Cancer. 2004; 100(8):1705-1711.
10. Kondziolka D, Kano H, Harrison GL, et al. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article. J Neurosurg. 2011;114(3):792-800.
11. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47(2):291-298.
12. Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol. 2005;23(9):2114-2116; author reply 2116-2117.
13. Metro G, Sperduti I, Russillo M, et al. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist. 2007;12(12):1467-1469; author reply 1469-1471.
14. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000; 18(11):2349-2351.
15. Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18(1):23-28.
16. van Vulpen M, Kal HB, Taphoorn MJ, et al. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy?. (Review). Oncol Rep. 2002;9(4):683-688.
17. Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev. 2013;39(3):261-269.
18. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-9290.
19. Kovtun YV, Audette CA, Mayo MF, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70(6):2528-2537.
20. Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011; 13(2):R46.
21. Niyazi M, Maihoefer C, Krause M, et al. Radiotherapy and "new" drugs-new side effects? Radiat Oncol. 2011;6:177.
22. Schwer AL, Kavanagh BD, McCammon R, et al. Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009; 73(5):1352-1357.
23. Voutsas IF, Mahaira LG, Fotopoulou K, et al. Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab. Int J Radiat Biol. 2013; 89(5):319-325.
24. Liang C, Tao Y, Shen C, et al. Erbin is required for myelination in regenerated axons after injury. J Neurosci. 2012;32(43): 15169-15180.
25. Yang H, Ling W, Vitale A, et al. ErbB2 activation contributes to de-differentiation of astrocytes into radial glial cells following induction of scratch-insulted astrocyte conditioned medium. Neurochem Int. 2011;59(7):1010-1018.
26. Chen Y, Swanson RA. Astrocytes and brain injury. J Cereb Blood Flow Metab. 2003;23(2):137-149.
27. Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157-1163.